ABVC BIOPHARMA, INC. — 2019 Form 10-K Summary
Filing identity and period: The supplied filing is for American BriVision (Holding) Corporation, for the fiscal year ended December 31, 2019, and was signed May 15, 2020. The issuer name differs from the request metadata; verify the filing’s relationship to ABVC Biopharma, Inc. The filing says it was submitted late under the SEC’s COVID-19 filing extension because pandemic-related restrictions disrupted access to staff, advisors, and company facilities.
Business context and reporting period
The company describes itself as a clinical-stage biopharmaceutical business, operating through drug-development, medical-device, and contract development and manufacturing (CDMO) units. Its pipeline includes six drug candidates in oncology, ophthalmology, and central nervous system indications, plus the ABV-1701 vitreous substitute device. Most candidates remained in development; the company reported no product royalty revenue. BioLite and BioKey became wholly owned subsidiaries on February 8, 2019, so 2019 results include their operations from the merger date and are not fully comparable with 2018.
Financial performance and liquidity
| Metric | 2019 | 2018 |
|---|---|---|
| Revenue | $701,719 | $6,956 |
| Gross profit (loss) | $681,582 | $(178,324) |
| Operating expenses | $4,140,360 | $2,606,239 |
| Operating loss | $(3,458,778) | $(2,784,563) |
| Net loss | $(3,933,240) | $(6,064,530) |
| Net cash used in operating activities | $(3,134,526) | $(900,531) |
- Revenue increased by $694,763, primarily from the CDMO business. Management attributed the lower net loss mainly to reduced other expenses, including no comparable investment impairment charge, and additional MDD-project milestone income. SG&A rose by approximately $1.48 million, mainly due to professional fees and costs of the CDMO business.
- R&D expense was approximately $1.05 million, compared with $988,721 in 2018. The filing reports interest expense of $482,014 in 2019.
- At year-end, cash and cash equivalents were $144,295 and restricted cash was $16,148. Current assets were $878,238 against current liabilities of $6,814,193, producing a working-capital deficit of $5,935,955. Total liabilities were $7,052,628; total equity was a deficit of $124,817.
- Current liabilities included $1,918,500 of short-term bank loans, $2,007,500 of current convertible notes (including related-party notes), $100,200 of notes payable, and $425,689 due to related parties. The filing also reports $539,803 of undiscounted future minimum lease payments.
- Cash used in operations increased substantially year over year; financing activities provided $3,087,489, principally from bank loans and convertible notes. Year-end liquidity was therefore supported by financing, not operating cash generation.
Material changes, outlook, and risks
- The February 2019 mergers and May 2019 1-for-18 reverse stock split materially changed the business and share count. The company issued shares to acquire BioLite and BioKey; 19,478,168 shares were reported outstanding at December 31, 2019.
- The company recorded a $43.65 million goodwill write-down in connection with the BioKey merger, reflected as a reduction to additional paid-in capital. The filing also reports a $2.61 million equity-investment impairment in 2018 and none in 2019.
- Management stated that substantial doubt about the company’s ability to continue as a going concern no longer existed, citing approximately $1.60 million of May 2020 private-placement proceeds, management salary deferrals, April 2020 note conversions, and creditor agreements to defer repayment. These are post-year-end measures; year-end cash remained low relative to current liabilities.
- Subsequent to year-end, certain notes with approximately $1.45 million of principal and accrued interest were exchanged for common shares and warrants. In May 2020, the company also sold shares at $2.25 each with a warrant attached, exercisable at $6.00, according to the filing. The board authorized increasing common shares from 20 million to 100 million in April 2020.
- Pipeline milestones were plans, not guaranteed outcomes: the company planned an FDA End-of-Phase-II meeting for ABV-1504; estimated completion of the ABV-1505 Phase II Part I in Q3 2020; and planned Phase II starts for ABV-1702 and ABV-1703 in Q4 2020. Management noted that scarce MDS cases could prevent the ABV-1702 trial from starting as planned.
- COVID-19 disruptions had delayed business development and restricted some research, supplier inspections, and partner due diligence. Other principal risks include ongoing losses and financing needs, regulatory and clinical-trial uncertainty, dependence on partners and a single source for certain active ingredients, product-liability exposure (the filing says it lacked general product-liability insurance), related-party dealings, competition, and potential dilution.
- The independent auditor issued an unqualified opinion on the financial statements. Management concluded disclosure controls and internal control over financial reporting were ineffective, citing inadequate monitoring and lack of segregation of duties with a one-person financial staff. The auditor did not attest to internal-control effectiveness.
Important facts for investors to verify
- Confirm the registrant’s identity and continuity: the filing names American BriVision (Holding) Corporation, while the request names ABVC Biopharma, Inc.
- Review the full audited statements and notes, especially the composition and maturity dates of debt, related-party balances, lease obligations, and the basis for management’s going-concern conclusion.
- Verify the status and results of the stated clinical programs and whether planned 2020 milestones occurred; the filing gives plans and enrollment updates, not evidence of later completion or approval.
- Assess the terms, completed share and warrant issuances, creditor deferrals, and dilution from the post-year-end financings and note exchanges.
- Check whether the company remediated its ineffective controls and whether COVID-related operational constraints, licensing obligations, and supplier concentration affected subsequent performance.